✦ LIBER ✦

Guidance on the use of canakinumab in patients with cryopyrin-associated periodic syndrome in Japan

✍ Scribed by Yokota, Shumpei; Nishikomori, Ryuta; Takada, Hidetoshi; Kikuchi, Masako; Nozawa, Tomo; Kanetaka, Taichi; Kizawa, Toshitaka; Miyamae, Takako; Mori, Masaaki; Heike, Toshio; Hara, Toshiro; Imagawa, Tomoyuki

Book ID: 121635891
Publisher: Springer
Year: 2012
Tongue: English
Weight: 281 KB
Volume: 23
Category: Article
ISSN: 1439-7595
DOI: 10.1007/s10165-012-0769-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Use of Canakinumab in the Cryopyrin-Asso

Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome

✍ Lachmann, Helen J.; Kone-Paut, Isabelle; Kuemmerle-Deschner, Jasmin B.; Leslie, 📂 Article 📅 2009 🏛 Massachusetts Medical Society 🌐 English ⚖ 458 KB

Efficacy and safety of canakinumab thera

Efficacy and safety of canakinumab therapy in paediatric patients with cryopyrin-associated periodic syndrome: a single-centre, real-world experience

✍ Russo, R. A. G.; Melo-Gomes, S.; Lachmann, H. J.; Wynne, K.; Rajput, K.; Elefthe 📂 Article 📅 2013 🏛 Oxford University Press 🌐 English ⚖ 112 KB

Efficacy and Safety of Canakinumab in a

Efficacy and Safety of Canakinumab in a Large Cohort of Cryopyrin-Associated Periodic Syndrome (CAPS) Patients across All Severity Phenotypes

✍ Cartwright, R.; Smith, J.; Hawkins, P.; Kuemmerle-Deschner, J.; Hachulla, E.; Ko 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 44 KB

PSY5 A MARKOV MODEL TO ESTIMATE THE EFFE

PSY5 A MARKOV MODEL TO ESTIMATE THE EFFECT OF CANAKINUMAB ON THE PROGRESSION OF AA AMYLOIDOSIS IN PATIENTS WITH CRYOPYRIN-ASSOCIATED PERIODIC-FEVER SYNDROMES (CAPS)

✍ Gauthier, A; Jiang, Y; Roberts, D; Warburton, J; Hawkins, PN; Lachmann, HJ 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

The schedule of administration of canaki

The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age

✍ Roberta Caorsi, Loredana Lepore, Francesco Zulian… 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 563 KB

Canakinumab (ACZ885, a fully human IgG1

Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS)

✍ Kuemmerle-Deschner, Jasmin B; Ramos, Eduardo; Blank, Norbert; Roesler, Joachim; 📂 Article 📅 2011 🏛 BioMed Central 🌐 English ⚖ 412 KB